1-2 of 2
Mohamed Fouad
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-world (RW) use of fixed-duration (FD) ibrutinib+venetoclax (Ibr+Ven) in patients (pts) with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Pooled analysis of REALITY-worldwide (WW) and REALITY-2 prospective cohort studies

Free
Catherine Thieblemont, Emmanuelle Tchernonog, Talha Munir, Oliver Miles, Ingo Schwaner, Ugo Consoli, Vanessa Innao, Anna Mele, Danielle De Farias, Adriana Scheliga, Neil Kay, Ahmed Absi, Galia Stemer, Tamar Tadmor, Mark Hoffman, Brian Koffman, Boo Messahel, Sowmya Srikanthan, Erin Franceschini, Christopher Abbazio, Ping Xu, Christoph Tapprich, Claire Kavanagh, Mohamed Fouad, Lori Parisi, Mark Wildgust, Paolo Ghia
Journal: Blood
Blood (2025) 146 (Supplement 1): 3903.
https://doi.org/10.1182/blood-2025-3903
Published: 2025
Journal Articles

Initiating First-Line (1L) Fixed-Duration (FD) Ibrutinib and Venetoclax (Ibr+Ven) in Patients (Pts) with Chronic Lymphocytic Leukemia (CLL) Improves Overall Survival (OS) Outcomes to Rates Approximating an Age-Matched General European Population

Free
Paolo Ghia, Loic Ysebaert, Ann Janssens, Mohamed Fouad, Claudio Schioppa, Jose-Angel Hernandez Rivas, Alessandra Tedeschi
Journal: Blood
Blood (2024) 144 (Supplement 1): 3254.
https://doi.org/10.1182/blood-2024-203883
Published: 2024